Volume : 11, Issue : 02, February – 2024
Title:
A A REVIEW ARTICLE ON HYPERTENSIVE-CLONIDINE
Authors :
R. Jona Methusala*, M. Noor Basha
Abstract :
Clonidine is an antihypertensive medication that acts on alpha-adrenergic and imidazoline receptor agonists. Clonidine is an antihypertensive drug that lowers blood pressure and heart rate by relaxing the arteries and increasing the blood supply to the heart; it has other FDA-approved indications such as treatment of attention deficit hyperactivity disorder (ADHD) in children (FDA approval 2010); management of tics commonly found with Tourette syndrome; and adjunct therapy for severing cancer-related pain. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of clonidine, pertinent for interprofessional team members when indicated for therapy.
Clonidine is a centrally active antihypertensive agent effective in the treatment of mild, moderate and severe hypertension, alone or in combination with other drugs. Use of oral clonidine has often been limited by side effects which include dry mouth and drowsiness. Transdermal clonidine was therefore developed as an alternative to oral therapy. while avoiding the potential for decreased efficacy associated with trough levels. The transdermal therapeutic system is a laminate consisting of an external film impermeable to moisture and to the drug, a thin layer of active drug dispersed within a highly drug-permeable matrix, a membrane with a controlled intrinsic permeability regulating the rate of delivery of drug to the skin, and an adhesive coating that attaches the system to the skin surface. The permeation of drug through the skin occurs primarily by diffusion. Maximum reduction in blood pressure occurs 2 to 3 days after initial application, and is maintained for at least 7 days or until the system is removed. The rate at which clonidine is presented to the skin surface is controlled by the microporous membrane: this rate is the same for all strengths of transdermal clonidine, the amount of clonidine released being proportional to its surface area. Thus, the daily dose is regulated by the area of skin covered. Typically, steady-state plasma concentrations are reached on the fourth day after initial transdermal system application. The lack of dose dependency in half-life and renal clearance estimates emphasise that the transdermal absorption of clonidine is linear. The plasma clonidine concentration produced by a particular transdermal dose varies considerably between individuals as a result of interindividual variation in renal clearance. For this reason, it is recommended that dosages be titrated up from the smallest system (3.5 cm2) until the desired pharmacological effect has been obtained.
Cite This Article:
Please cite this article in press R. Jona Methusala et al., A Review Article On Hypertensive-Clonidine, Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1. Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988;259: 2863-6.
2. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990; 264: 1546-9.
3. Breslau N, Kilbey MM, Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991;48: 1069-74.
4. Zinneman M, Coryell WH, Black DW. Cigarette smoking and psychiatric illness [Abstract]. Proceedings of the 144th Annual Meeting of the American Psychiatric Association. New Orleans: American Psychiatric Association, l99l: ll2.
5. Hughes JR, Hats kami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-7.
6. Hall SM, Munoz RF, Reus VI. Smoking cessation, depression, and dysphoria. NIDA Res Monogram 1990;105: 312-3.
7. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and major depression: a causal analysis. Arch Gen Psychiatry 1993; 50:36-43.
8. Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry 1992; 149:464-9.
9. Hall SM, Munoz R, Reus VI. Depression and smoking treatment: a clinical trial of an affect regulation treatment. NIDA Res Monogram 1992; 119:326.
10. Covey LS, Glassman AH. A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 1991; 86:991-8:
11. Manzon L, Nappe TM, DeMasters C, Maguire NJ. Clonidine toxicity. In: Stat Pearls. Treasure Island, FL: Stat Pearls Publishing, 2022. Accessed January 19, 2022.
12. Isbister GK, Heppell SP, Page CB, Ryan NM. Adult clonidine overdose: prolonged bradycardia and central nervous system depression, but not severe toxicity. Clin Toxicon (Phila). 2017;55(3):187–192. doi:10. 1080/15563650.2016.1277234
13. Amico K, Cabrera R, Ganti L. Outcomes following clonidine ingestions in children: an analysis of poison control center data. Int J Emerg Med. 2019;12(1):14. doi:10.1186/s12245019-0231-1
14. Taylor BN, Cassagnol M. Alpha adrenergic receptors. In: Stat Pearls. Treasure Island, FL: Stat Pearls Publishing, 2022. Accessed January 19, 2022.
15. Santer P, Anstey MH, Patrocliny MD, et al. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomized clinical trial. Intensive Care Med. 2020;46(10):1884– 1893. doi:10.1007/s00134-020-06216-x
16. Elson LS, Howland MA, Lewin NA, Smith SW, Gold frank LR, Hoffman RS. Gold franks Toxicologic Emergencies. 11th ed. New York, NY: McGraw-Hill; 2019.
17. Giovannetti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anish Prog. 2015; 62(1):31–39. doi:10.2344/0003-300662.1.31
18. Walters AS, Hening W. Clinical presentation and neuro pharmacology of restless legs syndrome. Clin Neuropharmacol1987; 10:225-37.
19. Banerji NK, Hurwitz LJ. Restless legs syndrome, with particular reference to its occurrence after gastric surgery. Br Med J 1970; 4:774-5.
20. Ekbom KA. Restless legs. Acta Med Scand 1945; Suppl 158:1-123.
21. Walters AS, Hening WA, Chokroverty S. Review and videotape recognition of idiopathic restless legs syndrome. Movement Discord 1991; 6:105-10.
22. Zoe A, Wagner ML, Walters AS. High-dose clonidine in a case of restless legs syndrome. Ann Pharmacotherapy 1994; 28:878-81.
23. Ekbom KA. Restless legs syndrome. Neurology 1960; 10:868-73.
24. Krueger BR. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc 1990; 65:999-1006.
25. . Montplaisir J, Godbout R, Boghen D, DeChamplain J, Young SN, Lapierre G, et al. Familial restless legs with periodic movements in sleep: electrophysiologic biochemical, and pharmacologic study. Neurology 1985; 35:130-4.
26. Callaghan N. Restless legs syndrome in uremic neuropathy. Neurology 1966; 16:359-61.
27. Harvey JC. Cholesterol crystal microembolization: a cause of the restless leg syndrome. South Med J 1976; 69:269-72. II. Nordlander NB. Therapy in restless legs. Acta Med Scand 1953; 145:453-7.
28. Lutz EG. Restless legs, anxiety and caffeinism. J CUn Psychiatry 1978; 39:693-8.
29. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 38:1845-8.
30. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993; 16:717-23.
31. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in the restless leg’s syndrome. Ann NeuroI1988; 24:455-8.
32. less leg syndrome”. N Engl J Med 1985 ;313: 1228-9. Steiner JC. Clonidine helps in restless legs syndrome. Neurology 1987;37(Suppl 1):278. [Abstract.)
33. Bastani B, Westervelt FB. Am J Kidney Dis 1987; 10:326-7.
34. Ausserwinkler M, Schmidt P. Erfolgreiche Behandlung des restless legs Syndroms bei chronischer Niereninsuffizienz mit Clonidine. Schweiz Med Wschr 1989; 119:184-6.
35. Bamford CR, Sandyk R. Failure of clonidine to ameliorate the symptoms of restless legs syndrome. Sleep 1987; 10:398-9.